The prolonged vacancy following Marty Makary’s May 2026 resignation has left Kyle Diamantas in the acting role without a permanent successor named, sustaining the tight contest between “no announcement by December 31” at 32.7% and Diamantas at 27.5%. Multiple candidates remain under White House review in an election-year Senate confirmation environment, where procedural delays and competing health-agency priorities have slowed momentum for any single nominee. Lower-priced options such as Brett Giroir, Sara Brenner, Stephen Hahn, and Grace Graham reflect limited public signals or endorsements that would shift trader consensus. Upcoming Senate calendar constraints and the lack of a short list or confirmation hearing schedule keep probabilities compressed, with any late formal announcement or withdrawal of contenders likely to reallocate odds quickly.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयाकाइल डायमांटस 13%
ब्रेट गिरोइर 8.2%
सारा ब्रेनर 7.2%
स्टीफन हान 6.2%
$18,953 वॉल्यूम
$18,953 वॉल्यूम
31 दिस, 2026
काइल डायमांटस
27%
स्टीफन हान
6%
ब्रेट गिरोइर
8%
ग्रेस ग्राहम
4%
सारा ब्रेनर
7%
31 दिसंबर तक कोई घोषणा नहीं
33%
काइल डायमांटस 13%
ब्रेट गिरोइर 8.2%
सारा ब्रेनर 7.2%
स्टीफन हान 6.2%
$18,953 वॉल्यूम
$18,953 वॉल्यूम
31 दिस, 2026
काइल डायमांटस
$6,163 वॉल्यूम
27%
स्टीफन हान
$1,802 वॉल्यूम
6%
ब्रेट गिरोइर
$3,007 वॉल्यूम
8%
ग्रेस ग्राहम
$4,151 वॉल्यूम
4%
सारा ब्रेनर
$2,798 वॉल्यूम
7%
31 दिसंबर तक कोई घोषणा नहीं
$1,032 वॉल्यूम
33%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The prolonged vacancy following Marty Makary’s May 2026 resignation has left Kyle Diamantas in the acting role without a permanent successor named, sustaining the tight contest between “no announcement by December 31” at 32.7% and Diamantas at 27.5%. Multiple candidates remain under White House review in an election-year Senate confirmation environment, where procedural delays and competing health-agency priorities have slowed momentum for any single nominee. Lower-priced options such as Brett Giroir, Sara Brenner, Stephen Hahn, and Grace Graham reflect limited public signals or endorsements that would shift trader consensus. Upcoming Senate calendar constraints and the lack of a short list or confirmation hearing schedule keep probabilities compressed, with any late formal announcement or withdrawal of contenders likely to reallocate odds quickly.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
बाज़ार खुला: May 12, 2026, 7:59 PM ET
वॉल्यूम
$18,953समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The prolonged vacancy following Marty Makary’s May 2026 resignation has left Kyle Diamantas in the acting role without a permanent successor named, sustaining the tight contest between “no announcement by December 31” at 32.7% and Diamantas at 27.5%. Multiple candidates remain under White House review in an election-year Senate confirmation environment, where procedural delays and competing health-agency priorities have slowed momentum for any single nominee. Lower-priced options such as Brett Giroir, Sara Brenner, Stephen Hahn, and Grace Graham reflect limited public signals or endorsements that would shift trader consensus. Upcoming Senate calendar constraints and the lack of a short list or confirmation hearing schedule keep probabilities compressed, with any late formal announcement or withdrawal of contenders likely to reallocate odds quickly.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
वॉल्यूम
$18,953समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...The prolonged vacancy following Marty Makary’s May 2026 resignation has left Kyle Diamantas in the acting role without a permanent successor named, sustaining the tight contest between “no announcement by December 31” at 32.7% and Diamantas at 27.5%. Multiple candidates remain under White House review in an election-year Senate confirmation environment, where procedural delays and competing health-agency priorities have slowed momentum for any single nominee. Lower-priced options such as Brett Giroir, Sara Brenner, Stephen Hahn, and Grace Graham reflect limited public signals or endorsements that would shift trader consensus. Upcoming Senate calendar constraints and the lack of a short list or confirmation hearing schedule keep probabilities compressed, with any late formal announcement or withdrawal of contenders likely to reallocate odds quickly.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न